| Ytd | -69.91% | |
| 1y | -34.46% |
| Open | 0.69 | Prev Close | 0.70 | Low | 0.66 | High | 0.70 | Mkt Cap | 105.03M |
| Vol | 887.30K | Avg Vol | 1.74M | EPS | -0.86 | P/E | -0.77 | Forward P/E | -0.77 |
| Beta | 2.32 | Short Ratio | 5.48 | Inst. Own | 86.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 0.76 | 200-d Avg | 1.01 | 1yr Est | 15.50 |
GUTS News
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health NASDAQ: GUTS said its Revita endoscopic procedure showed durable weight-maintenance r
Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.16) per share which missed the analyst
BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Compan
BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Compan
GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, co
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance
Fractyl Health Inc. (NASDAQ:GUTS) reported Wednesday one-year results from the Midpoint Cohort of it
Fractyl Health reported one-year REMAIN-1 data showing Revita reduced weight regain after GLP-1 ther
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
Fractyl Health NASDAQ: GUTS reported one-year data from the randomized midpoint cohort of its REMAIN
Key Findings:Dose-dependent durability confirmed at one year: In the full modified intention-to-trea
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in pat
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation an
BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Compan
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health NASDAQ: GUTS said it remains on track to report pivotal data for its Revita therapy i
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal dev
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company
Shares of Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) have earned an average rating of "Ho
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is h
Fractyl Health (NASDAQ: GUTS) used its fourth-quarter and full-year 2025 results call to sharpen its
